Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data

INTRODUCTION: The aim of the study was to estimate the overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib. MATERIAL AND METHODS: Real-world patients who received afatinib, erlotinib or gefitinib between 1 July 2012 and 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Brzozowska, Melania, Wierzba, Waldemar, Szafraniec-Buryło, Sylwia, Czech, Marcin, Majkut, Gabriela, Połowinczak-Przybyłek, Joanna, Potemski, Piotr, Śliwczyński, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641509/
https://www.ncbi.nlm.nih.gov/pubmed/34900041
http://dx.doi.org/10.5114/aoms.2018.80362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641509/
https://www.ncbi.nlm.nih.gov/pubmed/34900041
http://dx.doi.org/10.5114/aoms.2018.80362

Ejemplares similares